Advertisement
UK markets close in 37 minutes
  • FTSE 100

    7,879.76
    +31.77 (+0.40%)
     
  • FTSE 250

    19,406.77
    +66.63 (+0.34%)
     
  • AIM

    744.57
    +1.45 (+0.20%)
     
  • GBP/EUR

    1.1679
    +0.0012 (+0.10%)
     
  • GBP/USD

    1.2449
    -0.0007 (-0.06%)
     
  • Bitcoin GBP

    51,096.27
    +1,582.42 (+3.20%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • S&P 500

    5,045.82
    +23.61 (+0.47%)
     
  • DOW

    38,011.36
    +258.05 (+0.68%)
     
  • CRUDE OIL

    82.50
    -0.19 (-0.23%)
     
  • GOLD FUTURES

    2,387.80
    -0.60 (-0.03%)
     
  • NIKKEI 225

    38,079.70
    +117.90 (+0.31%)
     
  • HANG SENG

    16,385.87
    +134.03 (+0.82%)
     
  • DAX

    17,839.57
    +69.55 (+0.39%)
     
  • CAC 40

    8,034.13
    +52.62 (+0.66%)
     

EU drugs regulator says limited number of documents accessed in cyberattack

(Reuters) -Europe's medicines regulator said on Friday an investigation had so far revealed that a limited number of third-party documents were unlawfully accessed in a recent cyberattack and that it had engaged an external agency to carry out a full probe.

U.S. drugmaker Pfizer and German partner BioNTech said on Dec. 9 that documents relating to their COVID-19 vaccine were accessed unlawfully after the European Medicines Agency (EMA) disclosed the incident on the same day.

The EMA, which assesses medicines and vaccines for the European Union, said it remained fully functional and its timelines related to the evaluation and approval of COVID-19 vaccines and treatments were not affected.

Pfizer and BioNTech had earlier said they did not believe any personal data of trial participants was compromised.

ADVERTISEMENT

The regulator said it would continue to provide more information in due course.

The European Union has been waiting for the EMA to approve the vaccine from Pfizer and BioNTech. The regulator is expected to make an announcement on Dec. 21.

(Reporting by Radhika Anilkumar and Yadarisa Shabong in Bengaluru; Editing by Anil D'Silva)